The QualityStocks.net Daily Newsletter would like to highlight Mega Media Group, Inc. (MMDA) as “One to Watch” closing today at $0.11 with 136,688 shares traded (MMDA) was highlighted by AheadoftheBulls, Stock Guru, OTC Stock Exchange, Micro-Cap Opportunity, OTC Picks.
Mega Media Group, Inc. is a multi-media and entertainment company whose divisions offer a broad range of radio broadcasting services. Mega Media Group, Inc. through its subsidiary Pulse 87, which launched in mid February, announced they have secured the talent services of three veteran New York air personalities. Pulse 87 rounded out its talent lineup with Jewelz Lopez hosting Mid-days, Jimmy "Showboat" Fields will handle the Evening shift, and Laura Stylez joins for Weekends. The new D.J.'s will complement wildly popular The Star & Buc Wild Morning Show
The new hiring's could potentially bode well for New York radio, as all three new personalities seem tailor made for the new Rhythmic Top 40 radio station. The new hiring are also significant because the new host's come with a built in audience, which is the similar to the audience that Pulse 87 is targeting. . Mega Media Group, Inc. also announced an affiliate agreement with Apple i-Tunes that will allow visitors of to purchase music of the station's current play list through the i-Tunes on-line store, which is another means of generating passive income for Mega Media.
Mega Media Group, Inc. is a multimedia entertainment company with several subsidiaries that offer a broad range of services, including radio broadcasting via Pulse 87FM, a Rhythmic Top 40 Radio station serving the New York Tri-State Area, recording, digital editing, and music and video production and distribution.
The QualityStocks.net Daily Newsletter would like to highlight one of our former clients Novori Inc. (NOVO) as "One To Watch" closed today at $0.28 up 36.83% from $0.20 with 1,378,514 shares traded. (NOVO). was highlighted today by Small Cap Voice, OTC Picks and BoonMarket.com.
Novori is a leading online interactive retailer of diamond engagement rings and fine jewelry. Novori launched their website in 2005 and has built a well-respected brand by providing consumers with superior customer service and a better way to buy diamond engagement rings. Novori hit huge sales growth in its second year, with 2006 revenues exceeding 2005 by 2,374%. Due to strong holiday sales, online jewelry rose from the third fastest to become the # 1 fastest growing online industry for 2007 according to Comdex published statistics.
Novori announce the company has improved financial results for the quarter ended August 2007 compared to the same quarter for 2006. Some of the highlights include a 300% increase in gross profit, a 40% increase in revenues from $333,406 to $468,315. The company also saw a 117% increase in website traffic.
Novori announced that traffic to its website, www.novori.com , has increased substantially this month. The company anticipates reporting a significant increase in sales for the month of July 2007 as compared to July 2006 and anticipates having the comparison released on August 3, 2007.
Synplicity Inc. (SYNP) previously closed at $5.32 up 47.56% to $7.85 with 4,132,528 shares traded. (SYNP) was recently highlighted today by OTC Picks.
It was the first trading session since the buyout was announced, because the market was closed Friday for Good Friday. Early Monday D.A. Davidson analyst Matt Petkun downgraded the Sunnyvale, Calif.-based company to "Neutral" from "Buy." Petkun said he does not expect any other bidders and that the deal will likely be a "strong positive" for Synopsys.
Capital Corp of the West (CCOW), previously closed at $6.48 up 32.73% to $8.60 with 1,300,122 shares traded. (CCOW) was highlight recently by Knobias, OTC Picks Small Cap Investors and Stocks Stars.
Capital Corp of the West at the parent company of County Bank, has announced that, based on unaudited internal financial reports, its January and February 2008 month-end capital positions met or exceeded the regulatory definition of a well-capitalized financial institution. According to Don Briggs, chairman of the Regulatory Oversight Committee, “As of today we are well-capitalized.” Regulators define a well-capitalized institution as one that is above 10 percent in its risked-based capital ratio.
“We know that there have been questions in the marketplace and in the media about our 2007 earnings,” Mr. Briggs stated. “Like many other financial institutions in California’s Central Valley, the collapse of the real estate market significantly impacted our fourth quarter and our overall earnings for 2007. However, our performance in January and February 2008 has restored us to a well-capitalized position.”
County Bank customer deposits are insured by the FDIC to applicable limits and are backed by a bank with a solid community reputation that has been committed to serving its customers for more than 30 years. Briggs states, “County Bank looks forward to continuing its tradition of donating a portion of earnings each year in the 13 California counties it serves.”
Steadfast Holdings Group, Inc. (STHG) previously closing at $0.39 up 20.51% to $0.47 with 389,212 shares traded. (STHG) was highlighted today by Wall Street Grapvine, Stock Stars, OTC Stock Exchange and OTC Picks.
Steadfast Holdings Group, Inc. announced today that its flagship store in East Haven, Connecticut, reported a 40% increase in same store sales for the month of January, as compared to the same month in 2007. John Calash, CEO of Steadfast Holdings Group, Inc., stated, "This surge in our January sales proves to us that we have implemented the right product line expansion and sales development strategy. Given the general softness of consumer sales, we are delighted and excited by January's results, and believe that as we open additional stores, the sales success of our product line will be repeated again and again."
Cytomedix, Inc. (GTF) previously closing at $0.71 up 38.03% to $0.98 with 64,780 shares traded. (GTF) was highlighted today by Knobias.
Cytomedix, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a national coverage determination applicable to platelet rich plasma (PRP) gel for use on chronic wounds. This decision reaffirms an existing CMS 2003 decision and, in essence, continues non-coverage of PRP gel, citing inadequate evidence. In its decision memorandum, CMS stated, ``Suggestive evidence is now available for review; however this evidence is significantly limited in quality and therefore inadequate.''
Cytomedix, Inc. is disappointed with this outcome and believes that the evidence, including data from its own randomized, controlled, multi-center, double-blinded clinical trial, and other published studies, is adequate to support the reversal of the 2003 non-coverage decision, at least as related to diabetic foot ulcers, the focus of the Company's clinical trial and the emphasis of the Company's recent submissions to CMS. The Company is currently seeking a meeting with CMS to obtain clarification of further data and information that may be required by CMS to arrive at a positive coverage determination.
``We believe that the CMS determination tends to foster a two-tiered system whereby those who can afford to pay for PRP gel will receive it, but those who can't will go without access to a technology that, in our view, is supported by good science and evidence of clinical and cost effectiveness benefits and strongly deserves to be reimbursed through Medicare,'' said Dr. Kshitij Mohan, Chairman and Chief Executive Officer of Cytomedix. ``We are determined to see Medicare and other third-party payers cover this technology, and are evaluating the most expeditious path to achieve that goal,'' Dr. Mohan added.
Cytomedix, Inc. will also focus its efforts on its recently implemented sales and marketing strategy. The Company officially launched the AutoloGel(tm) System in the first quarter of 2008 and continues to devote significant resources and efforts toward its recently implemented sales and marketing strategy targeting the existing large non Medicare-sensitive markets such as Long-Term Acute Care Hospitals (LTAC's) and Veterans Administration Hospitals (VA's), which are not expected to be impacted by the CMS determination. A pharmaco-economic study commissioned by the Company and conducted by an independent consulting firm indicates that the AutoloGel(tm) System compares favorably against alternative wound management technologies for which comparable performance data was publicly available. The Company believes that this should be viewed positively by LTACs, which generally operate in a capitated payment environment, and VAs, which are sensitive to budgetary considerations.
``We will continue to invest in our sales and marketing efforts as we can now market our product for its intended use on chronic wounds, and we believe that we are the only company with a published, prospective, randomized, and controlled clinical trial and a PRP gel technology that has a chronic wound indication. To further hasten the commercialization of our product, we have been strengthening both our sales force and senior leadership of our sales, marketing, and commercialization efforts,'' said Dr. Mohan.
While maintaining a focus on the AutoloGel(tm) System, Cytomedix also plans to further strengthen its on-going efforts and discussions with other companies to commercialize other technologies based on its patents in areas such as hair restoration and angiogenic and anti-inflammatory peptides.
The QualityStocks Company Corner
The QualityStocks.net Daily Newsletter would like to highlight Rudy Beverage, Inc. (RUNU) as "One to Watch" for this week previously at $0.81 up 9.88% at $0.89 with
2,474,267
shares traded (RUNU) was highlighted by HotStocksRus,
AheadoftheBulls,
Best China Stocks .net,
Alphatrade
Rudy Beverages, Inc. recently announced two key partnerships, after announcing the addition of Pinnacle Brokers, Inc. to their nationally growing team of sales representatives, which has has begun proactively pitching Rudy Nutrition's healthier alternative "Rudy" branded products throughout the territories of Texas, Oklahoma and Louisiana. The company also announced an agreement with Canteen Franchise Group, the largest national vending operating company, to market and distribute Rudy Nutrition's healthier alternative sport drink and "Rudy" branded products.
Rudy Beverages, Inc. sits on the shoulders of Daniel "Rudy" Ruettiger, who once rode the shoulders of his teammates of the University of Notre Dame football team, which inspired the TriStar film, "Rudy." Still in the habit of setting and attaining goals, Ruettiger now focuses on creating a healthy line of beverages to help fight obesity, diabetes and related afflictions in America.
Rudy Beverage, Inc. recently announced the completion of the acquisition of Rudy Beverage, Inc. in exchange for 35,000,000 shares ("Rudy Shares") of its restricted common stock in exchange for 100% of the issued and outstanding shares of RBI.
Many of our regular readers will be familiar with Rudy Beverage, Inc. through our previous profiles for Global Beverage Solutions, Inc. which was a Distributor for Rudy Beverage's 32-ounce Rudy Revolution. The Rudy Revolution is marketed as a healthy alternative sports drink formulated with the sugar supplement natural sweetener Xylitol.
The company offers its Rudy Revolution" targeted for the active individual and "Rudy Flying Colors" which is a specialized drink specially formulated for children. Both formulas included a beneficial mixture of vitamins, electrolytes, carbohydrates and utilized xylitol as an alternative sweetener.
Rudy Beverage, Inc. engages in creating and distributing sports drinks for parents, kids, and athletes in the United States. Disclaimer
Rudy Beverage, Inc. Company Blog
Rudy Beverage, Inc. News:
Pinnacle Brokerage Joins the Rudy Nutrition Team Selling Healthy "Rudy" Branded Sport Drinks in Texas, Oklahoma and Louisiana
FOCUS 365 Brokerage Quarterbacking the West Coast Vending Sales of Rudy Nutrition's Healthy "Rudy"-Branded Sports Drinks
Quality Stocks News - Rudy Nutrition to Be Featured in Small Cap Stock Newsletter QualityStocks Daily
The QualityStocks.net Daily Newsletter would like to highlight Universal Detection Technology (UDTT) closed previously at $0.
0006
up 16.67% $0.0007 with
40,607,622
shares traded. (UDTT) was highlighted by Invest Source, OTC Picks, OTC Stock Exchange, Stock Stars and Stand Out Stocks
Universal Detection Technology that it has received a purchase order for for UDDT's bioterrorism detection kits. from its Chinese distributor, Kadinuo Science and Technology in Beijing. Kadinuo Science and Technology. Kadinuo Science and Technology has played a key role in the introduction and promotion of advanced radiation instruments in the Chinese market for over 10 years. Kadinuo Science and Technology is a strong regional supplier of emergency nuclear monitors, environmental radiation monitors, decontamination technologies.
Universal Detection Technology announced this week that it has joined forces with Innovative Biosensors, Inc. to address the market need for bio-threat detectors for clients dependent on accurate, rapid environmental assessments. The unique agreement, allows both IBI and UDTT to market and distribute their partner's biodection equipment, in addition to their own products, increasing both companies product reach and brand recognition in addition to inhancing their ability to to develop complete solutions for building and other security applications across government, military and commercial markets.
Universal Detection Technology announced that it has inked a deal to market a line of Anti-Microbial Products approved by the Environmental Protection Agency (EPA). The Product is designed to kill 99.9% of bacteria including Methicillin-resistant Staphylococcus (MRSA), E.coli, Norovirus, and Salmonella.
Universal Detection Technology announced that it has launched a new campaign to draw traffic to its new hub for online sales and marketing. UDTT's Silver Anti-Bac product range has been successfully tested on over 50 different organisms in over 2,000 applications. It is an effective killer of Methicillin-resistant Staphylococcus aureus (MRSA).
Universal Detection Technology shares climbed 15% recently, after the company announced that a site sponsored by the Department of Homeland Security highlighted UDTT's BSM-2000 Anthrax Detection System on the Responder Knowledge Base (RKB) website, the Primary source of information for First Responders. The company also announced it has received a purchase order from the Burbank Fire Department for its bioterrorism detection kits.
Universal Detection Technology has seen increased attention, after an article in the Washington Post, reported that the US military's lack of "sufficiently trained, ready forces available" to respond to nuclear, biological or chemical attacks. This potential threat is another wake up call regarding the use of chemical and bio weapons against the U.S., and further legitimizes and draws attention to the the wide range of applications for UDTT's monitoring technologies, and bio terrorism detection devices.
Universal Detection Technology recently announced a new purchase order from Security Solutions International (SSI) for UDTT's Ricin Toxin detection kits, and a non government related contract order worth over $50,000 from Gulf Security Solutions (GSS) to supply counter-WMD education, training and products. The company's products are utilized in counter-terrorism training and education to members of law enforcement and representatives from US Army and various other security and emergency response agencies.
Universal Detection Technology announced they will provide training during the 2008 Homeland Security S&T Stakeholders Conference organized by the Directorate for Science and Technology (S&T Directorate), the primary research and development arm of the United States Department of Homeland Security (DHS), to train first responders in bio terrorism detection. UDTT trained attendees in the use of lateral flow assay tests. The tests simulate a real world testing scenario to familiarize first responders with results they may encounter in the field.
Universal Detection Technology is a developer of monitoring technologies, including bio terrorism detection devices. Disclaimer
Universal Detection Technology Company Blog
Universal Detection Technology News:
Universal Detection Technology Inks Contract to Bring EPA Approved Anti-MRSA Products to Market
Universal Detection Technology Launches Campaign to Market Anti MRSA Products
Universal Detection Technology Receives Purchase Order From Burbank Fire Department for Bio terrorism Detection Kits
The QualityStocks.net Daily Newsletter would like to highlight Cord Blood America, Inc. ( CBAI) closed previoslyy at $0.02 up 5.26% to $0.02 with
643,290
shares traded ( CBAI) was highlighted by OTC Advisors, CEO Cast, Money TV and WallStreet Grand
Cord Blood America, Inc. shares climbed this week after the company announced that its subsidiary, RainMakers International, was featured with their logo on
Ken Schrader's car #49 at this weekends NASCAR UAW-Dodge 400 race at Las Vegas Motor Speedway. The race was featured on the FOX network.
Cord Blood America, Inc. announced that it believes the trend established in 2007 for states to legislate that consumers should be made aware of the advantages of umbilical cord blood storage will continue in 2008 and beyond. New York State in 2007 became the first in the nation to sign into law an Umbilical Cord Blood Bill mandating that the state's Department of Health develop a program to make the public aware of the benefits of umbilical cord blood banking. California subsequently followed, enacting legislation encouraging the collection of umbilical cord blood stem cells. The news could bode well for CBAI, after the mandate of programs that require State health department's to inform families about the safe benefits of umbilical cord blood storage, giving parents an opportune time to make a potentially life saving decision for the future.
Cord Blood America, Inc. announced preliminary results, which show a 500% the number of customers who preserve cord blood at the Company's state-of-the-art storage facilities. The company has increased its client base to more than 18,000 customers store blood, versus 3,000 customers the previous year. Based upon the current customer base, the Company is anticipating approximately $1.8 million in annual sales.
Cord Blood America announced that it has completed a private placement with institutional investors of 0% Senior Convertible Notes, at an original issue discount of 20%, in an aggregate principal amount of $1.9 Million. Midtown Partners & Co., LLC, was the placement agent in the transaction. In addition, the Company has also secured a $1 million acquisition line of credit, to be used strictly for acquisition and asset purchases.
Cord Blood America recently announced the companies third acquisition. The company announced that it has acquired the assets of CureSource, Inc., a private umbilical cord blood storage company headquartered in Charleston, South Carolina.
Cord Blood America announced that it has signed a consulting agreement with Midtown Partners & Co., LLC, to evaluate strategic alternatives to unlock value for its subsidiaries. Midtown Partners & Co., LLC is an investment bank focused on private placement investment banking opportunities. The company also announced this week that a letter to shareholders from CEO Matthew Schissler has been posted on the Company's website.
Cord Blood America saluted researchers at the University of Texas Medical Branch at Galveston who announced, in Science Daily, that they have engineered adult stem cells from human umbilical cord blood to produce insulin.
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. Disclaimer
Cord Blood America Daily Blog
Cord Blood America News:
Greatest Satisfaction Preserving Granddaughter's Cord Blood Stem Cells
Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race
Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greece's Leading Biotech Magazine
The QualityStocks.net Daily Newsletter would like to highlight Pressure BioSciences Inc. ( PBIO) as "One To Watch " previously at $4.00 up 6.25% at $4.25 with
3,541
shares traded ( PBIO) was recently highlighted by Red Chip, Taglich Dutton Associates and CEO Cast
Pressure BioSciences Inc. investors took note today after the company announced an increase in revenue from due impart to the sale of 20 PCT Sample Preparation.
The company was able to increase total revenue for 2007, which was $645,870 compared to $210,289 for 2006.
As of December 31, 2007, the Company had cash and cash equivalents of approximately $5.4 million, as compared to approximately $5.3 million on December 31, 2006.
The revenues and cash surplus were also boosted by an increase in products and services
Pressure BioSciences Inc. is one of our favorites from the recent Red Chip presenters. RedChip Companies, Inc., recently announced that it has issued a third quarter 2007 research update on Pressure BioSciences, Inc. The research report states "We maintain our Speculative Buy rating on PBIO stock and raise our 12-month price target to $10 per share from our earlier target of $7 given the Company's superior technology and our belief that sales will accelerate in FY 2008. We continue to believe that PBIO's current market price of $4.71 and a book value of $3.29 per share do not adequately reflect the inherent value of the Company."
Shares were also boosted on news that Dutton Associates updated its coverage of Pressure BioSciences maintaining a Strong Speculative Buy rating and a 12 month target price of $10. The 17-page report by Dutton senior analyst Denise T. Resnik, M.S. is available at www.jmdutton.com
Pressure BioSciences Inc. is a life sciences company, we have followed for much of this year, through our relationship with the Red Chip Conferences. Pressure BioSciences, Inc. shares bounced back recently after investors took note of recent positive news, which showed PBIO's ProteoSolve-LRS was successful in the identification of potential biomarkers in breast and colon cancer tissue. The study results were presented at the LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine Department of Pharmacology. The results present a viable alternative for proteomics researchers, who are faced with a number of challenges that can adversely affect the extraction of proteins from cells and tissues. The companies ProteoSolve-LRS method, when used in combination with its pressure cycling technology (PCT), will often allow proteomics researchers to achieve more rapid, more reproducible, and higher quality protein extraction results, enhancing the ability of researchers to find and identify new biomarkers of disease. In the past identifying patients with this disease who have been shown to benefit from therapy is difficult due to the lack of reliable bio markers.
Pressure BioSciences Inc. continues to make advancements regarding its pressure cycling technology (PCT). Frost & Sullivan announced that Pressure BioSciences, Inc. has been named the recipient of the 2007 North American Frost & Sullivan Award for Technology Innovation. The award is in recognition of the development and advancements regarding the combination of the Company's Pressure Cycling Technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit. The breakthrough is significant because it streamlines and improves upon the complex process of development of a method for the detergent-free extraction of proteins from lipid rich tissues, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.
Frost & Sullivan Senior Research Analyst Sandhya Kamath stated in the report "Protein expression from lipid rich tissues is crucial to understanding many disease states such as obesity, heart disease, diabetes, and certain cancer types, among others." "As a result, sample preparation is drawing attention in proteomic studies since it can affect the accuracy and the overall quality of the downstream analytical processes."
Pressure BioSciences, Inc. a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. Disclaimer
Pressure BioSciences, Inc. Blog
Pressure BioSciences, Inc. News:
Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
Pressure BioSciences, Inc. Announces Move to New Corporate Offices
|
